Back to top
more

Annovis Bio (ANVS)

(Delayed Data from NYSE)

$8.36 USD

8.36
786,199

+1.51 (22.04%)

Updated May 14, 2024 04:00 PM ET

After-Market: $8.50 +0.14 (1.67%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (92 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Soleno (SLNO) Soars as Prader-Willi Syndrome Study Meets Goal

by Zacks Equity Research

Soleno's (SLNO) shares rally as the late-stage study evaluating diazoxide choline for patients with Prader-Willi syndrome meets its primary and secondary endpoints.

Repligen (RGEN) to Acquire Fluid Management Company Metenova

by Zacks Equity Research

Repligen (RGEN) is set to acquire a Swedish company, Metenova, which focuses on manufacturing magnetic mixers for pharmaceutical and biotechnology applications.

Biophytis (BPTS) Soars 73% on Partnership With Skyepharma

by Zacks Equity Research

Biophytis (BPTS) gains on signing a partnership with Skyepharma, for the production of regulatory batches of its lead candidate, Sarconeos (BIO101).

Merck (MRK), Eisai Combo Therapy Fail Two Lung Cancer Studies

by Zacks Equity Research

Data from both late-stage studies evaluating Merck's (MRK) Keytruda and Eisai's Lenvima combination in certain types of metastatic non-small cell lung cancer, fail to achieve their primary endpoints.

FDA Expands Lilly (LLY) Jardiance Label in Chronic Kidney Disease

by Zacks Equity Research

Following the latest approval, Lilly's (LLY) Jardiance can access a target market that affects more than 35 million adults in the United States.

Travere (TVTX) Slumps 41% on Mixed Results From IgAN Drug Study

by Zacks Equity Research

Data from a confirmatory study shows that Travere's (TVTX) IgAN therapy did not achieve one of its confirmatory secondary endpoints. This will likely hurt the company's chances for the drug's full approval.

Jazz Pharma (JAZZ) Gets EU Nod for Cancer Drug Enrylaze

by Zacks Equity Research

The approval is based on data from a phase II/III study, which showed that treatment with Jazz's (JAZZ) Enrylaze achieved sustained asparagine activity in two cancer indications.

Puma's (PBYI) Alisertib Gets FDA's Orphan Drug Tag for SCLC

by Zacks Equity Research

Puma's (PBYI) alisertib receives the Orphan Drug designation from the FDA for treating patients with small cell lung cancer.

Relmada (RLMD) Up on Positive Data for Anti-Depressant Candidate

by Zacks Equity Research

Relmada's (RLMD) shares rise on long-term efficiency and safety data from the phase III study of its lead candidate REL-1017 to treat patients with major depressive disorder.

Evaxion (EVAX) Up on Partnership With Afrigen for Gonorrhea Jab

by Zacks Equity Research

Evaxion's (EVAX) shares gain as it collaborates with Afrigen Biologics to develop prophylactic mRNA vaccine targeting gonorrhea, based on Evaxion's EDEN technology.

FDA Accepts Merck (MRK) sNDA for Welireg in Renal Cell Carcinoma

by Zacks Equity Research

The FDA filing is supported by data from a late-stage study that shows that Merck's (MRK) Welireg achieved statistically significant and clinically meaningful improvement in progression-free survival.

Marinus (MRNS) Up 20% on Financial and Pipeline Updates

by Zacks Equity Research

Marinus' (MRNS) shares rise as it provides revenue and cash guidance for third-quarter 2023. The company also updates on the progress of its pipeline candidates targeting major central nervous system disorders.

Elutias (ELUT) Up on Sale of Orthobiologics Business for $35M

by Zacks Equity Research

Elutias (ELUT) gains on divestiture of Orthobiologics business unit for $35 million to Berkeley Biologics LLC, a wholly-owned subsidiary of GNI Group Ltd.

PTC Therapeutics (PTCT) Down on Negative CHMP Opinion for DMD Drug

by Zacks Equity Research

PTC Therapeutics (PTCT) plunges on negative opinion from the Committee for Medicinal Products for Human Use for conditional marketing and full marketing authorization of Translarna (ataluren) to treat nonsense mutation Duchenne muscular dystrophy.

CHMP Endorses AstraZeneca's (AZN) Enhertu in Lung Cancer

by Zacks Equity Research

Data from a mid-stage study shows that treatment with AstraZeneca's (AZN) Enhertu achieved strong and durable tumor responses in certain non-small cell lung cancer patients.

Vertex (VRTX) Gets Positive CHMP Opinion for Kaftrio Expanded Use

by Zacks Equity Research

Vertex's (VRTX) Kaftrio gets a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for extended use to treat younger age groups of two to five years old with cystic fibrosis.

Nektar (NKTR) Up on Positive New Data From Eczema Study

by Zacks Equity Research

Nektar (NKTR) gains on positive new data for its pipeline candidate, rezpegaldesleukin, evaluated from an early-stage study for treating atopic dermatitis.

Lyra (LYRA) Posts Upbeat Data on Rhinosinusitis Study, Stock Up

by Zacks Equity Research

Lyra (LYRA) gains on positive data from mid-stage study of LYR-220, treating patients with chronic rhinosinusitis who have had ethmoid sinus surgery.

Avalo (AVTX) Up 45% on Deal to Divest Certain Pipeline Drugs

by Zacks Equity Research

Avalo (AVTX) will receive an upfront payment of $150,000 on selling three compounds to AUG Therapeutics. The company is also eligible to receive milestone payments of up to $45 million.

Arcutis (ARQT) Files sNDA for Zoryve in Atopic Dermatitis, Stock Up

by Zacks Equity Research

Arcutis (ARQT) submits sNDA, seeking label expansion of Zoryve (roflumilast) cream 0.15% to treat patients with atopic dermatitis.

Moderna (MRNA), Immatics Ink Deal to Develop New Cancer Therapies

by Zacks Equity Research

The deal will combine Moderna (MRNA) and Immatics' (IMTX) proprietary platforms to develop innovative immunotherapies for cancer.

AstraZeneca (AZN) Posts Upbeat Data on Lung Cancer Drug Combo

by Zacks Equity Research

Data from a late-stage study shows that AstraZeneca's (AZN) Tagrisso combined with chemotherapy cut the risk of disease progression or death by 38% in certain lung cancer patients.

Arbutus (ABUS) to Focus on Hepatitis B Candidates, Stock Up

by Zacks Equity Research

Arbutus (ABUS) makes a strategic decision to focus on the development of hepatitis B virus therapies while discontinuing all coronavirus and oral RNA destabilizer programs.

Here's Why You Should Add ANI Pharmaceuticals (ANIP) to Your Portfolio

by Zacks Equity Research

ANI Pharmaceuticals (ANIP), a top-ranked stock, has a diverse portfolio of rare disease and generic medicines. Its Purified Cortrophin Gel is witnessing incremental sales in recent quarters.

Lisata (LSTA) Up on Positive Updates for Pancreatic Cancer Study

by Zacks Equity Research

Lisata's (LSTA) shares gain on a favorable outcome in interim futility analysis of its lead candidate, LSTA1, for pancreatic cancer.